Articles tagged with Vaccine Research
A new study from Aarhus University shows that heel-prick blood samples can measure antibodies against Group B Streptococcus in newborns, providing important insights into protection against serious infections. The method could contribute to the development of vaccines designed to protect infants against serious infections.
Pharmaceutical products can become contaminated with microorganisms, posing serious health risks. Sterilization processes vary in time and cost, with heat sterilization and gamma irradiation being traditional methods. Aseptic processing and sterile filtration are also used to produce sterile drug products.
Scientists at the University of Osaka have developed a method to recreate human B cells with germinal center features using three immune signals, which closely match those found in human tonsils. This breakthrough could help improve vaccine-induced antibody responses and identify targets for autoimmune disease.
Scientists at Queen Mary University of London discovered a way to overcome cell's natural defences against self-amplifying mRNA vaccines, enabling the production of significantly more of their target protein. This innovation could provide longer-lasting protection at lower doses, opening new possibilities in gene therapy, cancer immuno...
Researchers at MIT have found a way to stabilize lipid nanoparticles used to deliver RNA vaccines, making them more heat-resistant. This breakthrough could allow for wider distribution and enable novel administration methods like microneedle patches.
MIT researchers developed a new technique to produce lipid nanoparticles with precise control over size and shape, accelerating the development of RNA and DNA therapeutics. The automated system can produce particles of varying sizes and shapes, enabling targeted delivery to specific organs and tissues.
This technology rescues segmented negative-sense RNA viruses directly from complementary DNA in Vero cells, streamlining live-attenuated vaccine production. It utilizes non-cancerous Vero cells and employs triggered endosome escape transfection techniques for efficient delivery.
A vaccine that could lower the risk of dementia by half for those at high risk has sparked interest among older adults, with nearly 3 in 4 expressing interest in receiving such a vaccine. The survey results highlight a growing interest in vaccines that may prevent or delay dementia, a major concern for aging populations.
The AACR Cancer Progress Report 2026 highlights promising advances in cancer research, including FDA-approved new cancer drugs and the use of artificial intelligence. However, the report also underscores the need for sustained federal investment in cancer research to achieve a healthier future for all Americans.
A Korea University study found that an mRNA-based influenza vaccine elicits a more diverse and broader serum antibody repertoire than traditional vaccines. This leads to greater binding and neutralizing breadth against diverse influenza strains, suggesting potential for broader, longer-lasting protection.
A new saliva-based assay rapidly and accurately assesses flavivirus immunity by measuring multiple antibody classes in saliva. The test can distinguish between individuals with polytypic dengue virus immunity and those who have previously experienced both dengue virus and Zika virus infections.
Researchers have developed a technology that combines aminoglycoside antibiotics with PKZ18 analogs, resulting in up to an 8-fold increase in efficacy and reduced risk of microbial resistance. This synergy enables targeting of bacteria in various environments, expanding the therapeutic window.
The symposium celebrated Dr. Lee Ho-wang's 50th anniversary of Hantaan virus discovery, reviewing its historical significance and future research directions. Key findings included the development of Hantavax, the world's first epidemic hemorrhagic fever vaccine, and strategies for infectious disease response.
The vaccine, NXT-2, provides protection against pathogenic fungi while maintaining the balance of beneficial microbes in the gut. The study confirms that the vaccine's immune response does not significantly alter the resident fungi or bacteria populations in the gut.
Two studies on the 2026 Bundibugyo virus outbreak highlight new approaches to rapid diagnostics and vaccine preparedness. Diagnostic tests can be evaluated rapidly during an outbreak, and the 2026 virus may offer some cross-protection with existing Ebola vaccines.
Researchers at the University of Michigan Engineering have developed a process to manufacture flu vaccines in baker's yeast, producing virus-like particles that protect mice against multiple influenza strains. The approach aims to provide long-lasting protection, possibly even a lifetime, against multiple strains and subtypes.
A new flu vaccine, made using baker's yeast, has shown strong immune responses in mice, protecting against three different strains of flu, including those that mutate slowly. The vaccine targets the M2 protein, which is less likely to mutate and could provide broader protection against future flu strains.
Researchers explore bacterial extracellular vesicles as a tool for cancer diagnosis and treatment, with potential for targeted delivery of therapeutic molecules and immunotherapy. However, consistency and safety remain major challenges in this emerging field.
A study found geographic variation in measles-containing vaccine coverage among 7-year-old children in Northern California, highlighting the need for targeted vaccination efforts. The study assesses county-level data, revealing disparities in vaccination rates across different regions.
Researchers found that mRNA-based COVID-19 vaccines effectively protected Schistosoma-infected mice against SARS-CoV-2, with strong spike-specific antibody responses and CD4 T-cell immunity. The findings suggest that chronic helminth infection does not necessarily compromise vaccine-induced protection.
A new framework integrates all stages of carbohydrate vaccine development, from antigen production to clinical evaluation. The framework highlights emerging technologies like automated glycan assembly and AI-driven glycoscience to transform vaccine design.
A new study reveals that Republican lawmakers sponsored 86% of antivaccine bills introduced in state legislatures after the COVID-19 pandemic. Meanwhile, Democratic lawmakers supported provaccine bills, highlighting partisan polarization's impact on vaccine access and public health.
A vaccine targeting KRAS mutations was safe and stimulated durable immune responses in high-risk individuals. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some precancerous lesions shrank or stopped growing.
A study found that measles-containing vaccines were administered to only 15% of children in this age group between 2015 and 2025. This proportion remained stable over time, but disparities in vaccine uptake existed among minoritized racial and ethnic groups.
Genital herpes is a viral infection that establishes a lifelong infection by entering nerve cells and can be relieved with medication. Researchers have identified glycoprotein G as a promising target for a future vaccine, which could provide protection against HSV-2 spread to the nervous system.
A new study at RMIT University has identified conditions that help protect mRNA particles in dry vaccine patches, providing practical guidance for future patch design. This research could make future mRNA vaccines easier to store and distribute, particularly in lower-resource settings where cold-chain logistics are a barrier.
A new study found that BCG vaccines can modify Alzheimer's biomarkers in non-Alzheimer's participants, suggesting a potential biological explanation for the observed link between BCG vaccination and lower disease risk. The vaccine also promoted increased immune responses in healthy participants without Alzheimer's pathology.
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses. The vaccine resulted in the best HIV-fighting antibody response ever seen in primates, with human trials now underway.
A new vaccine, SchistoShield, has triggered an immune response and trained the body to remember it, according to researchers. The vaccine has shown effectiveness in both US and African populations, with robust cell-mediated effector and memory responses observed.
Researchers found that a daily spermidine supplement improved immune response to COVID-19 vaccination in older adults. Spermidine reduced markers of immunosenescence and stimulated autophagy, leading to higher antibody levels and better neutralizing activity against multiple viral variants.
Researchers developed an mRNA vaccine that targets neuroblastoma, delaying tumour development by 10-11 days and reducing tumour size by 70% in preclinical models. The vaccine uses peptide nanoparticles to target GPC2, a protein found on the surface of neuroblastoma cells.
Aberystwyth University experts Dr Kate Parsons and Dr Simon Payne will lead sessions on boosting vaccine uptake at the upcoming international meeting in Colombia. The workshop aims to bridge the gap between laboratory research and real-world impact by applying behavioural science principles to improve vaccine acceptance and delivery.
Researchers designed artificial proteins that simultaneously form pentagonal and hexagonal arrangements to create virus-like structures. These structures can stably carry drugs, genetic materials, and enzymes within their interior space.
In a phase 1 clinical trial, researchers found the LASSARAB vaccine to be safe and well-tolerated, inducing strong immune responses against Lassa fever and rabies. The vaccine demonstrated robust neutralizing antibody levels against the rabies virus, exceeding WHO's established threshold for protection.
A new study found that AI-powered chatbots can make vaccine-hesitant parents more likely to say they will immunize their children against HPV, but no more than standard written public health materials. Additionally, the effects of the chatbots did not last longer than those of government health materials.
A universal Sarbeco coronavirus vaccine has shown safety and no significant side effects in a human clinical trial, providing protection against multiple viruses, including SARS-CoV-2. The vaccine uses an AI-designed super-antigen to offer lasting protection against emerging virus threats.
A study of over 1,000 people vaccinated with TAK-003 in Catalonia found no serious adverse events and provided new evidence on the vaccine's short-term safety in travelers. The findings suggest that the dengue vaccine has a good tolerability profile among travelers from non-endemic regions.
The new vaccine adjuvant induces a strong mucosal immune response in the GI tract, which is crucial for eradicating polio. The researchers achieved a 20-fold increase in antibodies needed for mucosal immunity compared to the existing injectable polio vaccine.
A new study shows that a cancer vaccine in combination with immunotherapy reduces the risk of skin cancer recurrence and death by 49 percent. After five years, patients who received the combination therapy had a 68.8% chance of remaining cancer-free compared to 50.2% for those receiving immunotherapy alone.
Researchers at La Jolla Institute for Immunology have discovered that combining key vaccine ingredients could give the body the tools it needs to fight the entire family of arenaviruses with a single vaccine. This approach may protect against life-threatening infections from Lassa virus, Junin virus, and many other arenaviruses.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
The institution has established a state-of-the-art biosafety research center with integrated facilities for pathogen analysis, vaccine development, and treatment identification. Korea University Medicine plans to operate the first privately led full-cycle vaccine development platform in Korea.
Researchers created a new way to boost T-cell response to mRNA vaccines, yielding more powerful anti-cancer effects and stronger protection against infectious diseases. The innovation enabled the immune system to completely eradicate most tumors in mouse models.
Researchers discovered that CD4+ immune cells spot and attack the virus in the liver, leading to viral clearance. This finding points to a potential cure for hepatitis B, with therapies designed to activate these immune cells.
Scientists at La Jolla Institute for Immunology have characterized human antibodies capable of neutralizing measles virus. The new panel of human antibodies may form the basis for future medical therapies against measles infection, with a study showing a 500-fold lower viral load in a rodent model.
A Canadian study found that seasonal COVID-19 vaccination significantly reduced the risk of illness in 2025/26, with vaccine protection extending beyond its target strain. The vaccine was particularly beneficial for people aged 65 or older, offering 53% effectiveness against severe COVID-19.
A new study is exploring the effects of a nasal spray flu vaccine on children's immune systems, aiming to boost future protection and lower vaccine hesitancy rates. The study will provide valuable insights into how children develop immunity to influenza vaccines.
Researchers propose a new approach to overcoming vaccine hesitancy by framing vaccines in terms of personal autonomy and freedom, which showed greater willingness among those with higher concerns. The study suggests that traditional universal approaches may not be effective for everyone, highlighting the importance of individual values.
A systematic review of 59 studies found no association between aluminium-adjuvanted vaccines and serious or long-term health outcomes, including autism, type 1 diabetes, asthma, and myalgia. Persistent nodules or granulomas at the injection site were the most consistently documented reactions.
A growing gap in cervical cancer incidence rates between high- and low-income countries threatens to escalate unless prevention efforts are increased. Researchers urge universal vaccination for girls and boys, as well as catch-up campaigns, to close the gap and prevent nearly 37 million cases of cancer by the end of the century.
Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.
A nationally representative survey found that nearly 7 in 10 people trust vaccine scientists to act in their best interests, similar to medical scientists and scientists in general. The public perceives vaccine scientists as credible, self-correcting, and unbiased, with their work benefiting society.
A new Johns Hopkins University study reveals a significant link between following 'new right' media outlets and vaccine hesitancy. The research surveyed nearly 3,000 adults, finding that those who engage with these outlets are more than twice as likely to be hesitant about vaccines.
A new study found that infants receiving maternal RSV vaccination or Nirsevimab after birth had significantly lower RSV infection rates and fewer severe complications. The study showed a high uptake of the vaccines among pregnant patients and newborns, leading to declining rates of RSV-related illnesses.
Researchers at the University of Nebraska-Lincoln have developed a promising new vaccine approach against highly pathogenic bird flu (H5N1) that demonstrates strong efficacy in both mice and dairy cattle. The vaccine platform protects against multiple H5N1 strains and generates immunity in both the bloodstream and respiratory tract.
Recent studies have explored tumor vaccine platforms, including peptide, dendritic cell, and nucleic acid-based vaccines. Personalized neoantigen vaccines are refining precision in HCC treatment, but challenges persist due to immunosuppressive tumor microenvironments and heterogeneity.
Researchers developed a new flu vaccine approach targeting specific but distinct regions of the influenza virus protein. This method broadened the immune response, leading to broader protection against various strains. The study's findings have implications for fighting other fast-changing viruses like COVID-19 and RSV.
Researchers have found that COVID vaccines can train immune cells to remember the SARS-CoV-2 virus and protect against severe infection for years afterward. However, the continued spread of disease has scientists taking a closer look at how the immune system builds up immune memory over time.
Researchers found that obesity significantly impaired antibody production to a Pseudomonas aeruginosa vaccine in mouse models. The study suggests prioritizing tissue-resident immunity to boost protection against infections. Understanding this relationship addresses a significant gap in current vaccine research.
Researchers found that squalene-based adjuvants activate distinct pathways for vaccine protection and reactogenicity, including the role of IL-1β in enhancing efficacy and IL-1α in triggering local swelling. The study's findings could lead to safer vaccine design by targeting specific immune mechanisms.